Borrelidin

Isolation of vivomycin and borrelidin, two antibiotics with anti-viral activity, from a species of Streptomyces (C2989): M. Lumb, et al.; Nature 206, 263 (1965) | Genetic analysis of mutations causing borrelidin resistance by overproduction of threonyl-transfer ribonucleic acid synthetase: J. Frohler, et al.; J. Bacteriol. 143, 1135 (1980) | Increased levels of threonyl-tRNA synthetase in a borrelidin-resistant Chinese hamster ovary cell line: J.S. Gantt, et al.; PNAS 78, 5367 (1981) | Chinese hamster ovary cells resistant to borrelidin overproduce threonyl-tRNA synthetase: S.C. Gerken and S.M. Arfin; J. Biol. Chem. 259, 9202 (1984) | Isolation of a cDNA clone for human threonyl-tRNA synthetase: amplification of the structural gene in borrelidin-resistant cell lines: K.J. Kontis and S.M. Arfin; Mol. Cell. Biol. 9, 1832 (1989) | Borrelidin is an angiogenesis inhibitor; disruption of angiogenic capillary vessels in a rat aorta matrix culture model: T. Wakabayashi, et al.; J. Antibiot. 50, 671 (1997) | Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor: Y. Funahashi, et al.; Oncol. Res. 11, 319 (1999) | Borrelidin inhibits a cyclin-dependent kinase (CDK), Cdc28/Cln2, of Saccharomyces cerevisiae: E. Tsuchiya, et al.; J. Antibiot. 54, 84 (2001) | Anti-angiogenesis effects of borrelidin are mediated through distinct pathways: threonyl-tRNA synthetase and caspases are independently involved in suppression of proliferation and induction of apoptosis in endothelial cells: T. Kawamura, et al.; J. Antibiot. 56, 709 (2003) | Borrelidin induces the transcription of amino acid biosynthetic enzymes via a GCN4-dependent pathway: E.L. Eastwood & S.E. Schaus; Bioorg. Med. Chem. Lett. 13, 2235 (2003) | A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases: B. Ruan, et al.; J. Biol. Chem. 280, 571 (2005) | Borrelidin, a potent antimalarial: stage-specific inhibition profile of synchronized cultures of Plasmodium falciparum: A. Ishiyama, et al.; J. Antibiotics 64, 381 (2011) | A study on the effects of borrelidin on cardiovascular and intestinal smooth muscles: D. V. Bhikshapathi, et al.; Pharm. Lett. 5, 83 (2013) | Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin: I. G. Azcarate, et al.; Br. J. Pharmacol. 169, 645 (2013) | Identification of borrelidin binding site on threonyl-tRNA synthetase: M. Li, et al; Biochem. Biophys. Res. Comm. 451, 485 (2014) | Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo: E. M. Novoa, et al.; PNAS (USA) 111, E5508 (2014) | Borrelidin has limited anti-cancer effects in bcl-2 overexpressing breast cancer and leukemia cells and reveals toxicity in non-malignant breast epithelial cells: D. Gafiuc, et al.; J. Appl. Toxicol. 34, 1109 (2014) | Borrelidin or microorganism which produces it as inhibitor of potato scab disease: Y. Kobayashi, et al.; Jap. Kokai Tokkyo Koho JP 2014224102 (2014) | Borrelidin Induces the Unfolded Protein Response in Oral Cancer Cells and Chop-Dependent Apoptosis: A. Sidhu, et al.; ACS Med. Chem. Lett. 6, 1122 (2015) | Effect of borrelidin on hepatocellular carcinoma cells in vitro and in vivo: X. Gao, et al.; RSC Adv. 7, 44401 (2017) | Liposomal borrelidin for treatment of metastatic breast cancer: M. Jeong, et al.; Drug Deliv. Transl. Res. 8, 1380 (2018) | Aminoacyl-tRNA synthetase inhibition activates a pathway that branches from the canonical amino acid response in mammalian cells: Y. Kim, et al.; PNAS 117, 8900 (2020)